Volume 8.01 | Jan 14

Mammary Cell News 8.01 January 14, 2016
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
Study Reveals Potential Therapy Targets for Triple-Negative Breast Cancer
A multi-institutional international study has revealed new information about how molecules called long non-coding RNAs interact with HIF-1, a signaling pathway that is overexpressed in many cancers. HIF-1 has been shown to regulate breast cancer progression. [Press release from The University of Texas MD Anderson Cancer Center discussing online pre-publication in Nature Cell Biology] Press Release | Abstract
Request a Copy: Breast Cancer Wallchart
PUBLICATIONS (Ranked by impact factor of the journal)

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Researchers showed that a bivalent biparatopic antibody targeting two non-overlapping epitopes on HER2 can induce HER2 receptor clustering, which in turn promotes robust internalization, lysosomal trafficking, and degradation. [Cancer Cell] Abstract | Graphical Abstract

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment
Potential biomarkers for bone metastasis were identified using proteomic comparison of bone-metastatic, lung-metastatic, and nonmetastatic variants of human breast cancer MDA-MB-231 cells. Clinical validation was performed using immunohistochemical staining of tumor tissue microarrays from patients in a large randomized trial of adjuvant zoledronic acid. [J Natl Cancer Inst] Abstract

Identification of p62/SQSTM1 as a Component of Non-Canonical Wnt VANGL2–JNK Signaling in Breast Cancer
Scientists showed that the archetypal Wnt/PCP protein VANGL2 is overexpressed in basal breast cancers, associated with poor prognosis and implicated in tumor growth. [Nat Commun] Full Article

A Novel Cell-Penetrating Peptide Suppresses Breast Tumorigenesis by Inhibiting Beta-Catenin/LEF-1 Signaling
Researchers attempted to synthesize a peptide (TAT-NLS-BLBD-6) that could interfere with the interaction of β-catenin and LEF-1 at nuclei in human breast cancer cells. [Sci Rep] Full Article

Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools
By combining extensive single-cell gene expression profiling with three functional strategies for cancer stem cell enrichment including anchorage-independent culture, hypoxia, and analyses of low-proliferative, label-retaining cells derived from mammospheres, investigators identified distinct stem cell clusters in breast cancer. [Stem Cell Reports] Full Article | Graphical Abstract

Curcumin Suppresses Proliferation and Migration of MDA-MB-231 Breast Cancer Cells through Autophagy-Dependent Akt Degradation
Scientists experimentally revealed that curcumin treatment reduced Akt protein expression in a dose- and time-dependent manner in MDA-MB-231 breast cancer cells, along with an activation of autophagy and suppression of ubiquitin-proteasome system function. [PLoS One] Full Article


Clinical Verification of Sensitivity to Preoperative Chemotherapy in Cases of Androgen Receptor-Expressing Positive Breast Cancer
A total of 177 patients with resectable early-stage breast cancer were treated with neoadjuvant chemotherapy. Estrogen receptor, progesterone receptor, HER2, Ki67 and androgen receptor status were assessed immunohistochemically. [Br J Cancer] Full Article

Androgen Receptor Expression Predicts Beneficial Tamoxifen Response in Estrogen Receptor-α-Negative Breast Cancer
In patients with estrogen receptor-negative tumors, expression of androgen receptor (AR) predicted decreased recurrence rate with tamoxifen, whereas the opposite was seen in the AR− group. [Br J Cancer] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
Gene-Environment Interaction and Risk of Breast Cancer
The authors conclude that associations between the common genetic variants known today and breast cancer risk are only weakly modified by environmental factors, if at all. [Br J Cancer] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Register for Precision: Breast Cancer
Senior Scientific Teams Up with University of Michigan on In Vivo Breast Cancer Diagnostic
Manhattan Scientifics, Inc. announced that its Senior Scientific unit, developing a platform for the early detection of cancer and other human diseases, has established a Research Collaboration with The University of Michigan Medical School. The collaboration’s goal is to demonstrate the applicability of the company’s magnetic relaxometry technology for diagnosing and staging breast cancers. [Manhattan Scientifics, Inc.] Press Release

Saudi Food and Drug Authority Approves Gamma Medica’s LumaGEM® Molecular Breast Imaging Solution
Gamma Medica, Inc. announced the Saudi Food and Drug Authority has issued a Medical Device Marketing Authorization for their LumaGEM® breast imaging product. [Gamma Medica, Inc.] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
GE Healthcare, FedDev Ontario Commit CAD $40 Million for New CCRM-Led Center to Solve Cell Therapy Manufacturing Challenges
GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Center for Commercialization of Regenerative Medicine (CCRM) are building a center for advanced therapeutic cell technologies in Toronto with an investment of $40 million from GE and FedDev Ontario. [Center for Commercialization of Regenerative Medicine] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposia – Stem Cells and Cancer
March 6-10, 2016
Breckenridge, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Academic Surgical Pathologist – Breast Pathology (Northwestern University)

NEW Post-Doc Fellowship – Breast Cancer Functional Genomics (University of Cambridge)

NEW Post-Doc Fellowship – Breast Cancer Translational Research (University of Bern)

Post-Doc Fellowship – Breast/Ovarian Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Post-Doc Fellowship – Epidemiologist (German Cancer Research Center)

PhD Studentships – Various Projects (University of Cambridge)

Postdoctoral Researcher – Breast Tumor Image Analysis (Institute of Cancer Research)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

PhD Researcher – Cancer Signaling/Epigenetics/Tumor Biology (Institut Curie)

PhD Researcher – Personalized Immunotherapy for Cancer (ISPIC Consortium Members)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us